Brief: Rain Therapeutics Announces Collaboration With Tempus For Genomic Analysis In Planned Mdm2-Amplified Phase 2 Basket Trial Of Rain-32
03/06/2021 13:22
June 3 (Reuters) - Rain Therapeutics Inc RAIN.O :
* RAIN THERAPEUTICS ANNOUNCES COLLABORATION WITH TEMPUS FOR
GENOMIC ANALYSIS IN PLANNED MDM2-AMPLIFIED PHASE 2 BASKET TRIAL
OF RAIN-32
Source text for Eikon: ID:nGNX3hH0pm
Further company coverage: RAIN.O
((reuters.briefs@thomsonreuters.com;))
Recent news on Rain Oncology
See all newsBrief: Rain Enhancement Technologies Holdco - May Offer Up To $25 Million In Securities From Time To Time - SEC Filing
Brief: Rain Enhancement Technologies Holdco Inc - Q1 And Q2 2025 Financial Statements Should Not Be Relied Upon Due To Accounting Error - SEC Filing
Brief: Rain Oncology Pursuant To Proposed Deal With Pathos AI
Brief: Rain Oncology To Be Acquired By Pathos AI For $1.16 In Cash Per Share Plus Contingent Value Rights
Brief: Rain Oncology Q3 Net Income USD -7.034 Million